Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694870 | 0.81 | — | — | |
| SCHEMBL21267966 | 0.79 | — | — | |
| SCHEMBL3096199 | 0.78 | TSHR (0.38) | LMNATSHR | |
| SCHEMBL28576046 | 0.78 | TSHR (0.38) | LMNATSHR | |
| SCHEMBL16153750 | 0.78 | TSHR (0.38) | LMNATSHR | |
| SCHEMBL3096192 | 0.78 | TSHR (0.38) | LMNATSHR | |
| SCHEMBL3097246 | 0.76 | LMNA (0.39) | LMNATSHR | |
| SCHEMBL431429 | 0.76 | LMNA (0.39) | LMNATSHR | |
| SCHEMBL14337559 | 0.76 | LMNA (0.39) | LMNATSHR | |
| SCHEMBL3679182 | 0.75 | LMNA (0.56) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240218102-A1 | COMPOSITIONS WITH HIGH REFRACTIVE INDEX AND ABBE NUMBER | Johnson & Johnson Surgical Vision, Inc. | 2024-07-04 | — | — | US | disclosed |
| US-20240209129-A1 | OPHTHALMIC LENS MATERIALS AND DEVICES MADE THEREOF | Johnson & Johnson Surgical Vision, Inc. | 2024-06-27 | — | — | US | disclosed |
| WO-2024116106-A1 | OPHTHALMIC LENS MATERIALS AND DEVICES MADE THEREOF | Johnson & Johnson Surgical Vision, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024091573-A1 | CLOSED-LOOP OPTIMIZATION OF GENERAL REACTION CONDITIONS FOR HETEROARYL SUZUKI-MIYAURA COUPLING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4359422-A1 | A NOVEL COMPOUND ACTING AGAINST A SELECT GROUP OF BACTERIA | NORTHEASTERN UNIVERSITY (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024084448-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| WO-2001016138-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6191140-B1 | POTASSIUM CHANNEL MODULATORS; MUSCLE RELAXANTS; CONTROLLING CELL MEMBRANES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | disclosed |
| EP-1075466-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000071534-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000051986-A1 | CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024743-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000024741-A2 | DIHYDROPYRIDINE COMPOUNDS AND THEIR USE AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000007997-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS | ABBOTT LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | LMNA 1466/4885TSHR 4825/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | LMNA 2763/4885TSHR 3596/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | LMNA 4333/4885TSHR 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.